Virtus Biotech Clinical Trials ETF
12 hedge funds and large institutions have $3.71M invested in Virtus Biotech Clinical Trials ETF in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
29% less funds holding
Funds holding: 17 → 12 (-5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
53% less capital invested
Capital invested by funds: $7.9M → $3.71M (-$4.19M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$373K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$20.9K |
| 3 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$986K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$945K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$160K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$27.2K |
| 5 |
Morgan Stanley
New York
|
-$7.76K |
BBC Hedge Fund Activity: Q1 2016 in Review
12 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2016, worth a combined $3.71M — down 53% from $7.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was LPL Financial, adding an estimated $373K. The largest seller was Virtu KCG Holdings, cutting an estimated $986K.
- 12 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2016, down from 17 in Q4 2015.
- Funds reported $3.71M of Virtus Biotech Clinical Trials ETF stock for Q1 2016, down 53% quarter-over-quarter.
- 0 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2016 and 4 closed out, a net change of -4 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2016 was LPL Financial, an estimated $373K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2016 was Virtu KCG Holdings, an estimated $986K sold.
Based on aggregated 13F filings for Q1 2016.